9 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 6 Not applicable, 3 Phase 4, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 4, Active not recruiting 1, Recruiting 1 |
| Phase 4 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow HIV Coinfection: new trials by email Literature Review of HIV Coinfection trials Research Report on HIV Coinfection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis Targeted next-generation sequencing - Drug-resistant Tuberculosis, HIV Coinfection | Not applicable | Recruiting | University of California, San Francisco | 2500 | 2024-08-01 | 2026-01-26 |
| Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV No intervention - Monkeypox, HIV Coinfection | Completed | NEAT ID Foundation | 2000 | 2023-12-01 | 2025-08-13 | |
| Pharmacist-Led Intervention to Improve TB Treatment Adherence Educational counselling - Tuberculosis, Pulmonary, HIV Coinfection | Not applicable | Completed | Universiti Sains Malaysia | 383 | 2023-09-01 | 2025-08-07 |
| Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service patient-centered TB preventive therapy, TB preventive therapy adherence support - Tuberculosis, HIV Coinfection | Not applicable | Active not recruiting | Baylor College of Medicine | 6500 | 2023-07-11 | 2026-05-26 |
| TB-CAPT EXULTANT - HIV Concentrated urine with Xpert Ultra, Stool with Xpert Ultra - Tuberculosis, HIV Coinfection | Not applicable | Completed | Foundation for Innovative New Diagnostics, Switzerland | 1172 | 2022-09-05 | 2025-04-04 |
| HIV And Parasitic Infection (HAPI) Study Antiparasitic medication - HIV Coinfection | Not applicable | Completed | University of North Carolina, Chapel Hill | 120 | 2022-05-02 | 2025-07-16 |
| Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Isoniazid, Rifampicin, Ethambutol - Tuberculosis, Pulmonary Tuberculosis | Phase 2 | Completed | University of Massachusetts, Worcester | 112 | 2022-03-04 | 2026-08-06 |
| Supporting Treatment Outcomes Among PWID Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support - Hepatitis C, HIV Coinfection | Not applicable | Completed | Johns Hopkins University | 3000 | 2021-01-21 | 2025-04-08 |
| Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals Artemether-lumefantrine - HIV Coinfection, Malaria | Phase 4 | Unknown | Makerere University | 888 | 2021-01-18 | 2023-01-06 |
| Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF - Hepatitis C, HIV Coinfection | Phase 4 | Completed | University of Colorado, Denver | 10 | 2018-01-08 | 2021-02-11 |
| A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Maraviroc, Placebo - HIV Coinfection | Phase 4 | Completed | ViiV Healthcare | 138 | 2011-05-18 | 2017-12-06 |
| Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis Interferon-Gamma - HIV Coinfection, Aids/Hiv Problem | Phase 1 / Phase 2 | Completed | SPP Pharmaclon Ltd. | 78 | 2006-01-19 | 2024-01-25 |
HIV Infections (12) · Tuberculosis (4) · Tuberculosis, Pulmonary (3) · Hepatitis C (2) · Acquired Immunodeficiency Syndrome (1) · Directly Observed Therapy (1) · Latent Tuberculosis (1) · Lentivirus Infections (1) · Liver Diseases (1) · Malaria (1) · Mpox, Monkeypox (1) · Parasitic Diseases (1) · RNA Virus Infections (1) · Treatment Adherence and Compliance (1) · Tuberculosis, Multidrug-Resistant (1)
Blood-Borne Infections (12) · Communicable Diseases (12) · Genital Diseases (12) · Immune System Diseases (12) · Immunologic Deficiency Syndromes (12) · Infections (12) · Retroviridae Infections (12) · Sexually Transmitted Diseases (12) · Sexually Transmitted Diseases, Viral (12) · Urogenital Diseases (12) · Virus Diseases (12) · Lentivirus Infections (11) · RNA Virus Infections (11) · Actinomycetales Infections (6) · Bacterial Infections (6)
Albendazole (1) · Artemether, Lumefantrine Drug Combination (1) · Defecation (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Ethambutol (1) · Interferon-gamma (1) · Isoniazid (1) · Maraviroc (1) · Metformin (1) · Metronidazole (1) · Praziquantel (1) · Pyrazinamide (1) · Rifampin (1) · Tenofovir (1) · dolutegravir (1)
Baylor College of Medicine (1) · Foundation for Innovative New Diagnostics, Switzerland (1) · Johns Hopkins University (1) · Makerere University (1) · NEAT ID Foundation (1) · SPP Pharmaclon Ltd. (1) · Universiti Sains Malaysia (1) · University of California, San Francisco (1) · University of Colorado, Denver (1) · University of Massachusetts, Worcester (1) · University of North Carolina, Chapel Hill (1) · ViiV Healthcare (1)
France (2) · Malawi (2) · Poland (2) · South Africa (2) · Spain (2) · Tanzania (2) · Uganda (2) · United Kingdom (2) · United States (2) · Czechia (1) · Eswatini (1) · Germany (1) · Hungary (1) · India (1) · Lesotho (1)
Aner H Khan (1) · Hardy Kornfeld, MD (1) · Jennifer J Kiser, PharmD (1) · John Z Metcalfe, MD, PhD (1) · Melissa Reimer-McAtee, MD (1) · Nicolo Girometti, MD (1) · Pauline Byakika-Kibwika, PHD (1) · Robert S Wallis, MD, FIDSA (1) · Shruti H Mehta, PhD MPH (1) · Sunil S Solomon, PhD MBBS MPH (1) · Vladimir Shmelev, Doctor (1)
PMID 25923596, PMID 27924779, PMID 39148008, PMID 39572371, PMID 42105779, PMID 42379314, PMID 42560062
D43TW009340 (1), R01AI145555 (1), R01AI153213 (1), U01AI134585 (1)